Cytoxan

(cyclophosphamide)

ApprovedSmall molecule

Cyclophosphamide is a chemotherapy drug used to treat various cancers including lymphomas and leukemias, and is also used to treat certain autoimmune diseases like lupus and rheumatoid arthritis by suppressing the immune system.[2] Cytoxan is currently approved and in use across 341 indications[4].[1]

Cytoxan is one of 2443 small molecule programs targeting Leukemia. It is currently in Approved.

341

Indications

3,058

Total Trials

Active Trials

2,442

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

LeukemiaCompleted

Hematopoietic and Lymphoid Cell NeoplasmActive, not recruiting

Lung CancerRecruiting

RhabdomyosarcomaCompleted

Breast CarcinomaCompleted

Malignant GliomaNot yet recruiting

Systemic SclerosisTerminated

MyelofibrosisCompleted

Stem Cell TransplantTerminated

Hematological MalignanciesTerminated

LeukemiaPhase 3

Completed

Hematopoietic and Lymphoid Cell NeoplasmApproved

Active, not recruiting

Lung CancerPhase 3

Recruiting

RhabdomyosarcomaPhase 3

Completed

Breast CarcinomaApproved

Completed

Malignant GliomaPhase 2

Not yet recruiting

Systemic SclerosisPhase 3

Terminated

MyelofibrosisPhase 2

Completed

Stem Cell TransplantPhase 2

Terminated

Hematological MalignanciesPhase 3

Terminated

Showing 10 of 340 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Adenocard

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Duragesic-100

CCephalon

Preclinical

2 7

Duragesic

CCephalon

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Tianeptine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Neuroblastoma

NCT02298348

Phase 1/2Recruiting

Advanced Solid Tumors

NCT05681650

Q2 2027

Phase 1/2Recruiting

Melanoma

NCT01898039

Phase 2Active, not recruiting

Breast Cancer

NCT06531447

Recruiting

Real-World Study

NCT05899621

Q4 2027

Phase 2Recruiting

Acute Leukemia of Ambiguous Lineage

NCT04440267

Clinical

Trials by Indication[1]

Breast Cancer33 trials

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Active, not recruiting·TThe National Center of Oncology, Azerbaijan·Phase 2·NCT06531447·200 enrolled

Combination Chemotherapy in Treating Women With Breast Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003519·2,778 enrolled

Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery

Completed·IImperial College London·Phase 3·NCT00963729·756 enrolled

Show 30 more trials

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT00679029·15 enrolled

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00455533·384 enrolled

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT00331552·30 enrolled

Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

Completed·UUniversity Hospital Birmingham·Phase 3·NCT00003577·2,000 enrolled

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer

Unknown status·HHeinrich-Heine University, Duesseldorf·N/A·NCT00309920·1,234 enrolled

A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00190671·103 enrolled

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT03101748·34 enrolled

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00129935·1,384 enrolled

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer

Completed·—·Phase 1·NCT00496665·25 enrolled

Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer

Unknown status·YYonsei University·Phase 2·NCT00994968·49 enrolled

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00028964

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Withdrawn·—·Phase 1/2·NCT00006123

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02978495·154 enrolled

Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

Terminated·UUniversity of Southern California·Phase 2·NCT01873833·10 enrolled

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

Completed·UUNICANCER·Phase 2·NCT02400567·125 enrolled

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00773695·150 enrolled

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 3·NCT00288002·1,500 enrolled

Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Unknown status·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 3·NCT00005581·1,000 enrolled

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Completed·YYale University·Phase 2·NCT01855828·50 enrolled

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00017095·1,856 enrolled

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00124111

Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer

Completed·RRuijin Hospital·Phase 4·NCT02549677·294 enrolled

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

Completed·SScottish Cancer Therapy Network·Phase 3·NCT00002581·1,000 enrolled

Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00008034·15 enrolled

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Terminated·HHoosier Cancer Research Network··NCT00235235·80 enrolled

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05981001·170 enrolled

Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients

Completed·BBorstkanker Onderzoek Groep·Phase 3·NCT01099436·250 enrolled

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Completed· Amgen logo

Amgen·Phase 2·NCT00115414

Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT01503905·600 enrolled

Lymphoma23 trials

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00299182·50 enrolled

Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

Withdrawn·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00005998

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00005089·71 enrolled

Show 20 more trials

Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Completed·CCancer Research Campaign Clinical Trials Centre·Phase 3·NCT00002576·200 enrolled

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Completed· Roche logo

Roche·Phase 1/2·NCT02055820·267 enrolled

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Active, not recruiting·—·Phase 1·NCT00641381·25 enrolled

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT02228512

High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00669812·60 enrolled

Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

Unknown status·CCommissie Voor Klinisch Toegepast Onderzoek·Phase 3·NCT00028717·400 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Completed·UUniversity College, London·Phase 2·NCT01679119·129 enrolled

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT01775475·7 enrolled

Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

Completed·—·Phase 1/2·NCT00562978·54 enrolled

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Active, not recruiting·BBenjamin Tomlinson·Phase 1·NCT03434769·31 enrolled

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

Recruiting·BBGI, China·Phase 1·NCT06224049·6 enrolled

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Unknown status· Amgen logo

Amgen·Phase 2·NCT00005959

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00562965·29 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 3·NCT00004112

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Completed·UUniversity of Chicago·Phase 1/2·NCT02213913·55 enrolled

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT00134082·31 enrolled

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00302003·287 enrolled

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00074178·22 enrolled

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

Withdrawn·—·N/A·NCT00110006

Acute Lymphoblastic Leukemia12 trials

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00494897·374 enrolled

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

Completed·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 3·NCT00613457·2,039 enrolled

Show 9 more trials

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

Completed·CChildren's Oncology Group·Phase 1·NCT00866307·104 enrolled

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Completed·PPETHEMA Foundation·Phase 4·NCT00526305·100 enrolled

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT03103971·55 enrolled

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Unknown status·NNational University Hospital, Singapore·Phase 4·NCT02894645·500 enrolled

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·UUniversity College, London··NCT01085617

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT01156883·76 enrolled

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Withdrawn·UUniversity of Washington·Phase 2·NCT02538926

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Multiple Myeloma9 trials

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT01689987·18 enrolled

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·—·Phase 2·NCT00941720·71 enrolled

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Completed·MMedical College of Wisconsin·Phase 2·NCT05032820·40 enrolled

Show 6 more trials

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT00450814·48 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003401

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Terminated·UUniversity of Washington·Phase 1/2·NCT00849251·31 enrolled

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00609167·63 enrolled

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00813150·96 enrolled

Chronic Lymphocytic Leukemia8 trials

Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00343447

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Completed·GGerman CLL Study Group·Phase 2·NCT00309881·75 enrolled

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Completed·CCancer Research UK·Phase 2·NCT00337246·56 enrolled

Show 5 more trials

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Completed·HHoag Memorial Hospital Presbyterian·Phase 2·NCT00049413

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Active, not recruiting·AAllogene Therapeutics·Phase 1/2·NCT04416984·160 enrolled

Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003764·280 enrolled

Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00006390

Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01076556·9 enrolled

71 more indications

Bone Marrow Transplantation7 trials

Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders

Completed·—·N/A·NCT00005893

Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002534

Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors

Completed·UUNICANCER·Phase 3·NCT00002566·280 enrolled

Show 4 more trials

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002547·280 enrolled

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Completed·VVirginia Commonwealth University·Phase 2/3·NCT00003187·19 enrolled

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002502

Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma

Unknown status·SScotland and Newcastle Lymphoma Group·Phase 3·NCT00003815

Leukemia7 trials

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00665990·49 enrolled

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00055653

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT04029038

Show 4 more trials

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00005977·83 enrolled

Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma

Unknown status·TThe Second Affiliated Hospital of Henan University of Traditional Chinese Medicine·Phase 1/2·NCT02685670·20 enrolled

Monoclonal Antibody Therapy, Cyclophosphamide, and Total-Body Irradiation Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Recurrent Acute Lymphocytic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003870·40 enrolled

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

Completed·—·Phase 1·NCT00057005·6 enrolled

Lupus Nephritis6 trials

The Iguratimod Effect on Lupus Nephritis (IGeLU)

Unknown status·RRenJi Hospital·Phase 2·NCT02936375·120 enrolled

Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis

Completed·ZZhejiang University·Phase 1·NCT01207297·40 enrolled

Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis

Completed·ZZhi-Hong Liu, M.D.·N/A·NCT00876616·362 enrolled

Show 3 more trials

Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study

Completed·—·Phase 2·NCT00976300·40 enrolled

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

Terminated·—·Phase 3·NCT01015456·59 enrolled

Multicenter Registry of Pediatric Lupus Nephritis in China

Unknown status·XXiqiang Dang··NCT03791827·1,200 enrolled

Metastatic Cancer5 trials

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01457131·2 enrolled

Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

Unknown status·TThe Christie NHS Foundation Trust·Phase 3·NCT00022178

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01218867·24 enrolled

Show 2 more trials

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT01273181·9 enrolled

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

No longer available·NNational Institutes of Health Clinical Center (CC)··NCT04135092

Stem Cell Transplantation5 trials

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·—·Phase 2·NCT00003116·66 enrolled

Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma

Unknown status·MMedical Research Council·Phase 3·NCT00002599·750 enrolled

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·NNorthwestern University·Phase 1·NCT00004904

Show 2 more trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT00004114

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Terminated·KKiadis Pharma·Phase 3·NCT02999854·63 enrolled

Neuroblastoma4 trials

Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma

Completed·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00365755

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Infants With Neuroblastoma

Unknown status·CChildren's Cancer and Leukaemia Group·N/A·NCT00287950·120 enrolled

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

Active, not recruiting·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT02298348·18 enrolled

Show 1 more trial

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Completed·—·Phase 3·NCT00002802·500 enrolled

Ovarian Cancer3 trials

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

Completed·LLoyola University·Phase 2·NCT00002474

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Completed·UUniversity of Chicago·Phase 1/2·NCT00003136·11 enrolled

OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)

Withdrawn·IImmetacyte Ltd·Phase 1/2·NCT04389229

Chronic Myelogenous Leukemia3 trials

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002598·30 enrolled

Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Completed·—·Phase 2·NCT00002592·40 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Safety and Efficacy2 trials

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Terminated·MMustang Bio·Phase 1/2·NCT04109482·3 enrolled

Safety and Efficacy of Campath in Nonmyeloablative Transplantation

Completed·MM.D. Anderson Cancer Center·N/A·NCT00038844·65 enrolled

Lymphoid Malignancies2 trials

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00048737·70 enrolled

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03056339·49 enrolled

Bone Marrow Transplant2 trials

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00005797·125 enrolled

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00134017·142 enrolled

Transplantation2 trials

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Completed·SStanford University·Phase 2·NCT00899847·9 enrolled

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Kidney Cancer2 trials

Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer

Terminated·SStanford University·Phase 1·NCT01943188·2 enrolled

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Completed·CChildren's Oncology Group·Phase 3·NCT00002611·3,031 enrolled

Multiple Sclerosis2 trials

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00014755·35 enrolled

High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis

Completed·—·Phase 2·NCT00040482·10 enrolled

Ovarian Epithelial Cancer2 trials

Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer

Unknown status·MMedical Research Council·Phase 3·NCT00002477

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Terminated·GGynecologic Oncology Group·Phase 3·NCT00002819

Advanced Solid Tumors2 trials

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

Completed·XXinqiao Hospital of Chongqing·Phase 1/2·NCT06556108·5 enrolled

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Recruiting·—·Phase 1/2·NCT05681650·30 enrolled

Graft Versus Host Disease2 trials

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Completed·MMedical College of Wisconsin·Phase 3·NCT03959241·431 enrolled

Relapsed or Refractory2 trials

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Unknown status·SSalarius Pharmaceuticals, LLC·Phase 1·NCT03600649·50 enrolled

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Recruiting·UUniversity Hospital Heidelberg·Phase 1/2·NCT03676504·68 enrolled

Melanoma2 trials

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Completed·SSt. Luke's Medical Center·Phase 2·NCT00002535

Modified Vaccine for High Risk or Low Residual Melanoma Patients

Recruiting·HHadassah Medical Organization·Phase 1/2·NCT01898039·50 enrolled

Mantle Cell Lymphoma2 trials

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Completed· Teva logo

Teva·Phase 3·NCT00877006·447 enrolled

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00041132·56 enrolled

Hematologic Malignancies1 trial

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Completed·KKeio University·Phase 1/2·NCT00270881·33 enrolled

R/R AML1 trial

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Recruiting·AARCE Therapeutics, Inc.·Phase 1/2·NCT06680752·49 enrolled

Non-Small Cell Lung Cancer1 trial

A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

Completed·CCell Genesys·Phase 2·NCT00089726·100 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

Approved for marketing· Gilead logo

Gilead··NCT04162756

Follicular Lymphoma1 trial

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

Acute Lymphoblastic Leukaemia1 trial

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Unknown status·SSabz Biomedicals·Phase 1·NCT04653493·22 enrolled

Treatment1 trial

LAL-BR/2001: Study Treatment to Low Risk ALL

Completed·PPETHEMA Foundation·Phase 4·NCT00526175·150 enrolled

Mesenchymal Stem Cells1 trial

Cord Blood Expansion on Mesenchymal Stem Cells

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00498316·98 enrolled

Glioblastoma Multiforme1 trial

Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme

Unknown status·—·Phase 1·NCT02844062·20 enrolled

Phase II1 trial

Phase II Trial GA101 Inbrutinib B CLL

Completed·FFrench Innovative Leukemia Organisation·Phase 2·NCT02666898·135 enrolled

Primitive Neuroectodermal Tumor1 trial

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002643·130 enrolled

Ewing sarcoma1 trial

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT01231906·642 enrolled

Medulloblastoma1 trial

Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02212574·6 enrolled

Toxicity1 trial

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed·UUniversity of Louisville·Phase 1·NCT02472392·10 enrolled

CAR T Cell Therapy1 trial

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Recruiting·—·Phase 1/2·NCT06481735·30 enrolled

Malignant Brain Tumors1 trial

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT00238173·2 enrolled

Pembrolizumab1 trial

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Completed·GGenexine, Inc.·Phase 1/2·NCT03752723·84 enrolled

Stage IV Ovarian Epithelial Cancer1 trial

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921

Microscopic Polyangiitis1 trial

Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)

Completed·UUniversity Medical Center Groningen·Phase 3·NCT00103792·84 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Acute Promyelocytic Leukemia1 trial

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled

Acute Myeloid Leukemia1 trial

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 1·NCT02057770·25 enrolled

Liver Transplant1 trial

Liver Transplantation With Tregs at UCSF

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03654040·42 enrolled

Pemphigus1 trial

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

Terminated·NNYU Langone Health·Phase 2·NCT00483119·9 enrolled

Renal Cell Carcinoma1 trial

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

Completed·—·N/A·NCT00073879

Celecoxib1 trial

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Completed·—·Phase 2·NCT00165451·20 enrolled

Refractory Solid Tumors1 trial

Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003288·12 enrolled

Rhabdomyosarcoma1 trial

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Embryonal Rhabdomyosarcoma

Unknown status·JJapan Rhabdomyosarcoma Study Group·Phase 2·NCT00245141·32 enrolled

Relapsed or Refractory B-cell Hematologic Malignancies1 trial

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recruiting·MMayo Clinic·Phase 1·NCT06191887·27 enrolled

Immunosuppressive Treatment1 trial

Different Immunosuppressive Treatment in iMN

Recruiting·PPeking Union Medical College Hospital·Phase 3·NCT04745728·200 enrolled

Advanced Cancer1 trial

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Completed·SSt. Vincent Medical Center - Los Angeles·Phase 2·NCT00002475·40 enrolled

Prostate Cancer1 trial

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01696877·29 enrolled

Stem Cell Transplant1 trial

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Metabolic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003662·90 enrolled

Myelofibrosis1 trial

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Completed·MMayo Clinic·Phase 2·NCT00445900·22 enrolled

R/R NHL1 trial

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Unknown status·GGC Cell Corporation·Phase 1/2·NCT03778619·9 enrolled

Metastatic Melanoma1 trial

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00091104·136 enrolled

Renal Cancer1 trial

Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00923390·5 enrolled

Chronic Granulomatous Disease1 trial

Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02282904·7 enrolled

Advanced Stage1 trial

HD12 for Advanced Stages

Completed·UUniversity of Cologne·Phase 3·NCT00265031

Withdrawn·AArtiva Biotherapeutics, Inc.·Phase 1/2·NCT05678205

Glioblastoma1 trial

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Terminated·IImmatics Biotechnologies GmbH·Phase 1·NCT01403285·6 enrolled

Intestinal Cancer1 trial

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Completed·IIntima Bioscience, Inc.·Phase 1/2·NCT04426669·23 enrolled

Newly Diagnosed1 trial

First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Completed·TThe Catholic University of Korea·Phase 2·NCT01004497·51 enrolled

Efficacy1 trial

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Completed·CCelltrion·Phase 3·NCT02162771·140 enrolled

Hematological Diseases1 trial

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00309842·213 enrolled

Acute Leukemia1 trial

Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00245115·7 enrolled

Myelodysplastic Syndrome1 trial

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00077116·31 enrolled

Side Effects1 trial

Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer

Unknown status·CChildren's Cancer and Leukaemia Group··NCT00897871·60 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

CYTOXAN

NDA NDA012142

Jan 1, 1982

CYTOXAN

NDA NDA012141

Sep 16, 2013

CYCLOPHOSPHAMIDE

NDA NDA203856

Jul 30, 2020

CYCLOPHOSPHAMIDE

NDA NDA212501

Aug 25, 2021

CYCLOPHOSPHAMIDE

NDA NDA210735

Jun 7, 2023

FRINDOVYX

NDA NDA210852

Jun 28, 2023

CYCLOPHOSPHAMIDE

NDA NDA217651

Sep 12, 2023

CYCLOPHOSPHAMIDE

NDA NDA217150

Sources

References

[1]
ClinicalTrials.gov — 3058 trial records for cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Cytoxan drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA217150). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Cytoxan. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Baxter Healthcare Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: BBaxter Healthcare Corporation

Patent Landscape[6]

Patent Cliff

Jun 26, 2035

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9662342Jun 26, 2035

10849916Jul 13, 2035

11382923Dec 1, 2035

12329767Feb 15, 2036

10993952Feb 15, 2036

Cytoxan

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Breast Cancer33 trials

Lymphoma23 trials

Acute Lymphoblastic Leukemia12 trials

Multiple Myeloma9 trials

Chronic Lymphocytic Leukemia8 trials

Bone Marrow Transplantation7 trials

Leukemia7 trials

Lupus Nephritis6 trials

Metastatic Cancer5 trials

Stem Cell Transplantation5 trials

Neuroblastoma4 trials

Ovarian Cancer3 trials

Chronic Myelogenous Leukemia3 trials

Safety and Efficacy2 trials

Lymphoid Malignancies2 trials

Bone Marrow Transplant2 trials

Transplantation2 trials

Kidney Cancer2 trials

Multiple Sclerosis2 trials

Ovarian Epithelial Cancer2 trials

Advanced Solid Tumors2 trials

Graft Versus Host Disease2 trials

Relapsed or Refractory2 trials

Melanoma2 trials

Mantle Cell Lymphoma2 trials

Hematologic Malignancies1 trial

R/R AML1 trial

Non-Small Cell Lung Cancer1 trial

Relapsed/Refractory B-cell Malignancies1 trial

Follicular Lymphoma1 trial

Acute Lymphoblastic Leukaemia1 trial

Treatment1 trial

Mesenchymal Stem Cells1 trial

Glioblastoma Multiforme1 trial

Phase II1 trial

Primitive Neuroectodermal Tumor1 trial

Ewing sarcoma1 trial

Medulloblastoma1 trial

Toxicity1 trial

CAR T Cell Therapy1 trial

Malignant Brain Tumors1 trial

Pembrolizumab1 trial

Stage IV Ovarian Epithelial Cancer1 trial

Microscopic Polyangiitis1 trial

Real-world Study1 trial

Acute Promyelocytic Leukemia1 trial

Acute Myeloid Leukemia1 trial

Liver Transplant1 trial

Pemphigus1 trial

Renal Cell Carcinoma1 trial

Celecoxib1 trial

Refractory Solid Tumors1 trial

Rhabdomyosarcoma1 trial

Relapsed or Refractory B-cell Hematologic Malignancies1 trial

Immunosuppressive Treatment1 trial

Advanced Cancer1 trial

Prostate Cancer1 trial

Stem Cell Transplant1 trial

Metabolic Disease1 trial

Myelofibrosis1 trial

R/R NHL1 trial

Metastatic Melanoma1 trial

Renal Cancer1 trial

Chronic Granulomatous Disease1 trial

Advanced Stage1 trial

Hematologic Cancer1 trial

Acute Leukemia of Ambiguous Lineage1 trial

Clinical Trial1 trial

Glioblastoma1 trial

Intestinal Cancer1 trial

Newly Diagnosed1 trial

Efficacy1 trial